This year has truly been a tale of two markets. For a five-week period in the first quarter, downside momentum in the stock market tied to the coronavirus disease 2019 (COVID-19) pandemic was unlike anything we'd ever seen before. But over the past 3.5 months, Wall Street has undertaken its strongest rally in more than two decades.
If 2020 has taught investors anything, it's the power of long-term investing and sticking with your initial investment thesis, even if some pretty big hiccups present themselves.
It's also taught investors that you don't need to be rich to become rich in the stock market. If you have $5,000 in cash at your disposal that won't be needed to pay bills or for emergencies, then you have more than enough capital to put to work in some of the fastest-growing industries in the new bull market. Here are five industries you'd be smart to consider buying into right now with $5,000.
Image source: Getty Images.
If these industries were being presented in any particular order (which they aren't), cloud computing would likely be at the top of the list. Even before COVID-19 became a serious concern, we were already witnessing a steady transition toward remote and shared-work capabilities. COVID-19 simply provided a shot in the arm to facilitate this transformation even faster. In my mind, there's little question that cloud growth should consistently remain in the double-digits on an annual basis throughout this decade.
While there are no shortage of cloud service companies to choose from, e-commerce giant Amazon (NASDAQ:AMZN) might be the preferred stock to own. Amazon Web Services (AWS) operates as an infrastructure-as-a-service player, which is a fancy way of saying that it supplies small and medium-sized businesses with the tools necessary to form the building blocks of their cloud-based platform. In just a five-quarter stretch, AWS has grown from 11% of Amazon's total sales to 13.5% of total sales, while accounting for the lion's share of its operating income during the first quarter.
Make no mistake about it, high-margin cloud sales are going to generate insane amounts of cash flow for Amazon and other cloud-service providers.
Image source: Getty Images.
If there's such a thing as a no-brainer industry to buy, it's cybersecurity. No matter how well or poorly the U.S. and global economy are performing, hackers don't take time off. This makes the hardware and subscription protection services provided by cybersecurity companies an absolute necessity. And with more businesses pushing into the cloud than ever before, there's a growing need for more sophisticated security solutions.
Here, I continue to be a fan of what Palo Alto Networks (NYSE:PANW) is doing. In recent quarters, Palo Alto has deemphasized physical firewall products in favor of higher-margin subscription and support services. This will lead to more consistent revenue recognition and should help reduce what little client churn the company is contending with. And yes, it'll help improve operating margins over the long run, too.
Palo Alto has also diversified its product offerings through numerous bolt-on acquisitions. Look for the company to continue spending aggressively on innovation and inorganic growth to improve its cloud-protection market share.
Image source: Getty Images.
The cannabis industry gets a bit of a bad rap given that the bubble finally burst in pot stocks over the past 15 months. Supply issues to our north, high tax rates in select U.S. markets, and financing concerns throughout North America have coerced caution from investors.
But this is still an industry where tens of billions of dollars in sales are conducted annually in the black market. It's expected that these illicit channels will gradually give way to legal sales over time and offer the North American marijuana industry a double-digit growth opportunity throughout much of the 2020s.
An intriguing name to consider here is Green Thumb Industries (OTC:GTBI.F). Green Thumb is a multistate operator with 48 open dispensaries and licenses to open as many as 96 stores in a dozen states. Green Thumb is currently generating about two-thirds of its revenue from higher-margin derivatives, rather than dried cannabis flower, which is a big reason it looks to be on the cusp of recurring profitability.
Furthermore, Green Thumb has established a significant presence in Illinois, which opened its doors to recreational weed sales on Jan. 1, 2020, as well as Nevada, which has the potential to lead the nation in cannabis spending per-capita by mid-decade.
Image source: Getty Images.
Another industry that looks set to come into its own is the Internet of Things (IoT). By IoT, I'm talking about wireless devices that can communicate with other wireless devices, as well as data centers. Like marijuana, IoT was hyped up too quickly in the 2010s, but has now had time to mature. This growing focus on technology making our lives easier is bound to have a positive impact on IoT companies for years to come.
The name to watch here is NXP Semiconductors (NASDAQ:NXPI), which generated almost half of its revenue last year from the automotive industry, with industrial equipment, communications, and mobile comprising the remainder of sales in 2019. In particular, NXP is a leader in self-driving and sensor equipment used in a number of newer automobiles. Between 2018 and 2021, NXP expects to have delivered a compound annual growth rate of 7% to 10% (this includes 2021 as an estimate), which is outpacing the CAGR for the IoT auto market of 5% to 7% over this same time frame.
Additionally, don't overlook other growth drivers for NXP, such as mobile payment adoption, the rollout of 5G networks, and its scalability in industrial processing applications.
Image source: Getty Images.
Last, but not least, don't forget about the personalized medicine push. Anything that caters to individual patient needs, especially during a pandemic, is likely to see demand improve significantly over the long run.
As a perfect example, take a closer look at Teladoc Health (NYSE:TDOC), which provides telemedicine visits for patients. Not only are these virtual visits critical during the pandemic to ensure that sick people remain in their homes, but it's a considerably more convenient method of arranging a consultation with a physician. It also doesn't hurt that telemedicine visits tend to be cheaper for insurance providers.
During the pandemic-impacted first quarter, Teladoc reported an absurd 92% uptick in virtual visits, with its paying membership increasing by 61% to 43 million people in the United States. Visit-fee-only access increased by a whopping 89%, as well. Though there's little question that Teladoc Health will continue to lose money in the near-term as it enhances its platform and makes complementary acquisitions, it clearly has the tools necessary to become a major player in personalized health over the next decade.
See the article here:
Got $5,000? Buy Stocks in These 5 Industries Now - Motley Fool
- Oncology Precision Medicine Market Research, Industry Trends and Global Forecasts, 2035 - Rising Partnership and ... - PR Newswire - March 18th, 2024
- 3 Precision Medicine Stocks That Could Benefit From the Industry's Rise - InvestorPlace - March 18th, 2024
- Prime Editing Approach Provides a Faster, More Effective Way to Screen for Cancer Mutations - Inside Precision Medicine - March 18th, 2024
- Global Genomics Industry Research 2024-2031: Rising Adoption of Personalized Medicines and Gene Therapies ... - PR Newswire - March 18th, 2024
- CAR T-Cell Therapy Successfully Used to Treat Brain Tumors - Inside Precision Medicine - March 18th, 2024
- Revolutionizing Wellness: The Power of Personalised Health Tech - AutoGPT - March 18th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- AI and predictive medicine: Recent advances - News-Medical.Net - March 10th, 2024
- Personalized medicine is coming, but who will have access to it? - AAMC - March 10th, 2024
- Why personalized medicine is a business trend to watch in 2024 - HealthLeaders Media - March 10th, 2024
- AI helps cardiologists deliver personalized healthcarebut there is still plenty of work to do - Cardiovascular Business - March 10th, 2024
- Q&A: How AI and wearable technologies are transforming medicine - EMS1.com - March 10th, 2024
- HealthTech Revolution: Wearables, AI, and the Personalized Future of Healthcare - GearBrain - March 10th, 2024
- Redefining Healthcare: The Rise of Personalized Medicine and the Shift from Conventional Care - Medriva - March 10th, 2024
- Dr Kalinsky on Unanswered Questions Regarding Genomic Testing in HR+ Breast Cancer - OncLive - March 10th, 2024
- Chemotherapy Plus High Doses of Radiation Effective for Treating Non-Small Cell Lung Cancer - Inside Precision Medicine - January 17th, 2024
- It's Time to Fully Embrace Precision Medicine's Promise in Pediatrics - Healthcare Innovation - January 17th, 2024
- Special Report: Radiation Oncology Takeaways from RSNA23 - Imaging Technology News - January 17th, 2024
- Advanced Therapeutics Pharmaceutical Outsourcing Market to Surge at a CAGR of 4.4% by 2034 Amid Growing ... - PR Newswire - January 17th, 2024
- Simulations of the human body and advanced data promise more personalized medical treatment - Medical Xpress - January 17th, 2024
- United States Single Cell Genomics and Proteomics Growth Opportunities: The Integration of Multi-Omics Data to Drive ... - PR Newswire - January 17th, 2024
- Advances Usher In Era of Personalized Treatment for Obesity - Gastroenterology & Endoscopy News - January 17th, 2024
- Unveiling the Reality of Personalized Medicine: Yale Study Highlights Limitations in Current Predictive Models - Medriva - January 17th, 2024
- Digital Twins: The Future of Personalized Healthcare - BNN Breaking - January 17th, 2024
- Healthcare in 2024: A Vision of the Future | Future of Healthcare Predictions - Medriva - January 17th, 2024
- Utilization of the microbiome in personalized medicine - Nature.com - December 22nd, 2023
- Focusing on Women's Health - Inside Precision Medicine - December 22nd, 2023
- Revolutionizing Healthcare: Innovations in Regenerative Medicine Offer Hope - Inside Precision Medicine - December 22nd, 2023
- AI in Genomics Market Predicted to Grow at CAGR of 40.6% by 2031, with Revenue $9.8 Billion - PharmiWeb.com - December 22nd, 2023
- Innovative Technologies Transforming Cancer Treatment - BNN Breaking - December 22nd, 2023
- Antisense Oligonucleotides Industry Poised to Reach US$ 5519.6 Million by 2033-FMI Projection - PharmiWeb.com - December 22nd, 2023
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022
- AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions... - June 8th, 2022
- Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022 - Endocrinology Network - June 8th, 2022